Clinical Trial Update: A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma [EARLY_Phase 1]

View source ↗

Summary

Clinical trial update describing a Phase 1 study of acalabrutinib plus rituximab followed by brexucabtagene autoleucel in previously untreated high-risk mantle …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• Rituxan (rituximab)
• Tecartus (brexucabtagene autoleucel)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma, Mantle Cell Lymphoma | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING